


ORION PHARMA LIMITED AND ITS SUBSIDIARIES
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
AS AT AND FOR THREE MONTH PERIOD ENDED 30 SEPTEMBER 2022
(FIRST QUARTER)

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Condensed Consolidated Statement of Financial Position (Unaudited)
As at 30 September 2022

Particulars	Notes	Amount In BDT	
		30-Sep-22	30-Jun-22
Assets			
Non-Current Assets		32,122,383,394	29,352,468,375
Property, Plant and Equipment	6	13,674,739,714	13,826,413,931
Right of use Assets	7	43,437,477	49,473,939
Construction Work in Progress	8	9,860,325,995	9,133,148,194
Investment in Associates	10	2,587,563,000	386,739,000
Other Investments	11	5,956,317,209	5,956,693,311
Current Assets		23,475,533,831	18,754,570,672
Inventories	12	2,321,080,813	2,345,666,013
Trade and Other Receivables	13	18,307,501,789	14,905,340,747
Advances, Deposits & Prepayments	14	1,349,732,947	1,365,595,495
Fixed Deposit with Banks	15	32,347,588	31,833,589
Cash and Cash Equivalents	16	1,464,870,695	106,134,828
Total Assets		55,597,917,226	48,107,039,047
Shareholders' Equity and Liabilities			
Shareholders' Equity		21,679,883,331	19,312,524,742
Share Capital	17	2,340,000,000	2,340,000,000
Share Premium		8,016,892,026	8,016,892,026
Reserves	18	4,172,106,833	1,978,094,161
Retained Earnings	19	7,150,884,472	6,977,538,555
Non - Controlling Interest	20	1,462,229,214	1,456,338,901
Total Equity		23,142,112,545	20,768,863,643
Non-Current Liabilities		19,513,007,209	17,901,488,970
Provision for Decommissioning of Assets		143,405,563	143,405,563
Long Term Loan	21	19,205,250,264	17,600,571,555
Lease Obligation	22	32,576,606	35,265,395
Deferred Tax Liability	23	131,774,776	122,246,457
Current Liabilities		12,942,797,472	9,436,686,434
Current portion of Long Term loan	21.1	408,151,600	387,466,840
Current Portion of Lease Obligation	22.1	24,313,106	31,664,304
Short term loans	24	561,323,761	563,904,269
Trade and Other Payables	25	11,166,347,858	7,719,509,102
Employee Benefits	26	140,623,632	131,388,616
Unclaimed/Unpaid Dividend		13,372,592	13,517,701
Accrued Expenses	27	628,664,923	589,235,603
Total Equity & Liabilities		55,597,917,226	48,107,039,046
Number of Shares Used to Compute NAV		234,000,000	234,000,000
Net Asset Value (NAV) Including Revaluation Surplus	33	92.65	82.53
Net Asset Value (NAV) Excluding Revaluation Surplus		84.75	74.62



Chairman




Managing Director



Director



Chief Financial Officer



Company Secretary

ORION PHARMA LIMITED
Condensed Statement of Financial Position (Unaudited)
As at 30 September 2022

Particulars	Notes	Amount In BDT	
		30-Sep-22	30-Jun-22
Assets			
Non-Current Assets		23,032,921,942	20,190,686,601
Property, Plant and Equipment	6a	7,369,778,261	7,449,132,157
Right of use Assets	7	43,437,477	49,473,939
Construction Work in Progress	8	9,860,325,995	9,133,148,194
Investment in Subsidiaries	9	1,017,000,000	1,017,000,000
Investment in Associate	10	2,587,563,000	386,739,000
Other Investments	11a	2,154,817,209	2,155,193,311
Current Assets		11,639,438,442	10,070,289,890
Inventories	12a	1,317,969,046	1,331,788,513
Trade and Other Receivables	13a	7,825,226,679	7,800,159,206
Advances, Deposits & Prepayments	14a	1,061,569,575	816,094,952
Fixed Deposit with Banks	15	32,347,588	31,833,589
Cash and Cash Equivalents	16a	1,402,325,554	90,413,630
Total Assets		34,672,360,384	30,260,976,491
Shareholders' Equity and Liabilities			
Shareholders' Equity		15,176,266,723	12,878,578,498
Share Capital	17	2,340,000,000	2,340,000,000
Share Premium		8,016,892,026	8,016,892,026
Reserves	18a	3,808,683,918	1,612,623,288
Retained Earnings	19a	1,010,690,779	909,063,184
Non-current Liabilities		17,505,611,264	15,451,040,063
Long term loan	21a	17,341,259,882	15,293,528,211
Lease obligation	22	32,576,606	35,265,395
Deferred tax liability	23	131,774,776	122,246,457
Current Liabilities		1,990,482,398	1,931,357,930
Current portion long term loan	21a.1	408,151,600	387,466,840
Current portion of finance lease obligation	22.1	24,313,106	31,664,304
Short term loans	24	561,323,761	563,904,269
Trade and other payables	25a	400,325,428	390,344,399
Employee benefits	26a	56,325,446	50,868,462
Unclaimed/Unpaid Dividend		13,372,592	13,517,701
Accrued expenses	27a	526,670,465	493,591,956
Total Equity & Liabilities		34,672,360,384	30,260,976,491
Number of Shares Used to Compute NAV		234,000,000	234,000,000
Net Asset Value (NAV) Including Revaluation Surplus	33a	64.86	55.04
Net Asset Value (NAV) Excluding Revaluation Surplus		59.02	49.19


 Chairman
 Managing Director
 Director
 Chief Financial Officer

 Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES

Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (Unaudited)
For Three Month Period Ended 30 September 2022

Particulars	Notes	Amount In BDT	
		July 2022 to September 2022	July 2021 to September 2021
Revenue from Net Sales	28	3,914,680,319	1,187,728,531
Cost of Goods Sold		(329,644,723)	(320,794,448)
Cost of Power Generation		(3,039,051,525)	(463,091,283)
Gross Profit		545,984,071	403,842,799
Operating Expenses		(265,354,116)	(253,250,824)
General & Administrative Expenses		(103,125,571)	(97,255,674)
Selling & Distribution Expenses		(162,228,544)	(155,995,150)
Profit from Operation		280,629,955	150,591,976
Financial Expenses	29	(69,136,219)	(49,013,336)
Non Operating Income/ (Loss)	30	13,606,264	432,941
Net Profit from Operation		225,100,000	102,011,581
Workers Profit Participation Fund		(10,719,048)	(6,262,069)
Net Profit before Tax		214,380,952	95,749,512
Income Tax		(41,905,909)	(28,572,950)
Current Tax (Expenses)/Income	31	(32,051,631)	(24,478,746)
Deferred Tax (Expenses)/Income		(9,854,278)	(4,094,204)
Net Profit after Tax		172,475,044	67,176,562
Share of Profit from Associate		2,790,900	3,189,600
Net Profit		175,265,944	70,366,163
Less: Non Controlling Interest (share of operating profit)		(5,890,313)	(73,657)
Net Profit after Tax before Other Comprehensive Income		169,375,631	70,292,505
Other Comprehensive Income		2,197,981,607	110,203,587
Fair Value Gain of Marketable Securities		(377,452)	10,012,620
Fair Value Gain on Investment in Associate		2,198,240,752	101,234,889
Share of Other Comprehensive Income		(207,652)	123,511
Deferred tax Income (Expenses) on Revaluation Surplus of PPE & Fair Value Changes of Marketable securities		325,959	(1,167,433)
Total Comprehensive Income Attributable to Ordinary Shareholders		2,367,357,239	180,496,092
Number of Shares Used to Compute EPS		234,000,000	234,000,000
Earnings Per Share (EPS)	32	0.72	0.30


Chairman


Managing Director


Director


Chief Financial Officer


Company Secretary

ORION PHARMA LIMITED

Condensed Statement of Profit or Loss and Other Comprehensive Income (Unaudited) For Three Month Period Ended 30 September 2022

Particulars	Notes	Amount In BDT	
		July 2022 to September 2022	July 2021 to September 2021
Revenue from Net Sales	28.a	733,999,700	708,039,294
Cost of Goods Sold		(329,644,723)	(320,794,448)
Gross Profit		404,354,977	387,244,845
Operating Expenses		(251,118,017)	(241,696,430)
General & Administrative Expenses		(88,889,472)	(85,701,280)
Selling & Distribution Expenses		(162,228,544)	(155,995,150)
Profit from Operation		153,236,960	145,548,416
Financial Expenses	29.a	(20,267,339)	(19,404,160)
Non Operating Income/ (Loss)	30.a	12,791,670	432,941
Net Profit from Operation		145,761,291	126,577,197
Workers Profit Participation Fund		(6,941,014)	(6,027,486)
Net Profit before Tax		138,820,277	120,549,711
Income Tax		(41,905,909)	(28,572,950)
Current Tax (Expenses)/ Income	31	(32,051,631)	(24,478,746)
Deferred Tax (Expenses)/ Income		(9,854,278)	(4,094,204)
Net Profit after Tax		96,914,368	91,976,761
Share of Profit from Associates		2,790,900	3,189,600
Net Profit after Tax before Other Comprehensive Income		99,705,268	95,166,361
Other Comprehensive Income		2,197,981,607	110,203,587
Fair Value Gain of Marketable Securities		(377,452)	10,012,620
Fair Value Gain on Investment in Associate		2,198,240,752	101,234,889
Share of Other Comprehensive Income		(207,652)	123,511
Deferred tax Income (Expenses) on Revaluation Surplus of PPE & Fair Value Changes of Marketable securities		325,959	(1,167,433)
Total Comprehensive Income attribute to Ordinary Shareholders		2,297,686,875	205,369,948
Number of Shares Used to Compute EPS		234,000,000	234,000,000
Earnings Per Share (EPS)	32.a	0.43	0.41

 Chairman
  Managing Director
  Director
  Chief Financial Officer
  Company Secretary


ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Condensed Consolidated Statement of Changes in Equity (Unaudited)
For Three Month Period Ended 30 September 2022

Particulars	Amount in BDT				
	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total
Balance at 01 July 2022	2,340,000,000	8,016,892,026	1,978,094,161	6,977,538,555	19,312,524,742
Net Profit after Tax	-	-	-	169,375,631	169,375,631
Fair Value Gain / (Loss) on Investment in Associate	-	-	-	-	-
Fair Value (Loss)/Gain on Marketable Securities	-	-	2,198,240,752	-	2,198,240,752
Fair Value (Loss)/Gain on Marketable Securities	-	-	(377,452)	-	(377,452)
Adjustment for sale of Mkt. Securities	-	-	1,350	-	1,350
Share of Other Comprehensive Income	-	-	(207,652)	-	(207,652)
Adjustment of Deferred tax on Revaluation Surplus	-	-	325,959	-	325,959
Depreciation on Revaluation Surplus	-	-	(3,970,285)	3,970,285	-
Balance at 30 September 2022	2,340,000,000	8,016,892,026	4,172,106,833	7,150,884,472	21,679,883,331

For Three Month Period Ended 30 September 2021

Particulars	Amount in BDT				
	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total
Balance at 01 July 2021	2,340,000,000	8,016,892,026	1,904,852,372	6,400,990,484	18,662,734,883
Net Profit after Tax	-	-	-	70,292,505	70,292,505
Fair Value Gain / (Loss) on Investment in Associate	-	-	101,234,889	-	101,234,889
Fair Value (Loss)/Gain on Marketable Securities	-	-	10,012,620	-	10,012,620
Adjustment for sale of Mkt. Securities	-	-	4,919,681	-	4,919,681
Share of Other Comprehensive Income	-	-	123,511	-	123,511
Adjustment of Deferred tax on Revaluation Surplus	-	-	(1,167,433)	-	(1,167,433)
Depreciation on Revaluation Surplus	-	-	(2,547,844)	2,547,844	-
Balance at 30 September 2021	2,340,000,000	8,016,892,026	2,017,427,797	6,473,830,832	18,848,150,654


Chairman


Managing Director


Director


Chief Financial Officer


Company Secretary

ORION PHARMA LIMITED
Condensed Statement of Changes in Equity (Unaudited)
For Three Month Period Ended 30 September 2022


Particulars	Amount in BDT				
	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total
Balance at 01 July 2022	2,340,000,000	8,016,892,026	1,612,623,288	909,063,184	12,878,578,498
Net Profit after Tax	-	-	-	99,705,268	99,705,268
Fair Value Gain / (Loss) on Investment in Associate	-	-	2,198,240,752	-	2,198,240,752
Fair Value (Loss)/Gain on Marketable Securities	-	-	(377,452)	-	(377,452)
Adjustment for sale of Mkt. Securities	-	-	1,350	-	1,350
Share of Other Comprehensive Income	-	-	(207,652)	-	(207,652)
Adjustment of Deferred tax on Revaluation Surplus	-	-	325,959	-	325,959
Depreciation on Revaluation Surplus	-	-	(1,922,327)	1,922,327	-
Balance at 30 September 2022	2,340,000,000	8,016,892,026	3,808,683,918	1,010,690,779	15,176,266,723

For Three Month Period Ended 30 September 2021


Particulars	Amount in BDT				
	Ordinary Share Capital	Share Premium	Reserves	Retained Earnings	Total
Balance at 01 July 2021	2,340,000,000	8,016,892,026	1,536,805,467	518,496,227	12,412,193,719
Net Profit after Tax	-	-	-	95,166,361	95,166,361
Fair Value Gain / (Loss) on Investment in Associate	-	-	101,234,889	-	101,234,889
Fair Value (Loss)/Gain on Marketable Securities	-	-	10,012,620	-	10,012,620
Adjustment for sale of Mkt. Securities	-	-	4,919,681	-	4,919,681
Share of Other Comprehensive Income	-	-	123,511	-	123,511
Adjustment of Deferred tax on Revaluation Surplus	-	-	(1,167,433)	-	(1,167,433)
Depreciation on Revaluation Surplus	-	-	(2,171,981)	2,171,981	-
Balance at 30 September 2021	2,340,000,000	8,016,892,026	1,649,756,753	615,834,569	12,622,483,348


Chairman


Managing Director


Director


Chief Financial Officer


Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES

Condensed Consolidated Statement of Cash Flows (Unaudited)

For Three Month Period Ended 30 September 2022

Particulars	Amount In BDT	
	July 2022 to September 2022	July 2021 to September 2021
A. Cash Flows from Operating Activities :		
Cash Received from Customers	778,821,937	1,069,704,060
Cash Paid to Suppliers	(326,001,524)	(709,704,700)
Cash Payment for Operating Expenses	84,807,108	5,468,502
Cash Generated from Operation	537,627,521	365,467,861
Income Taxes Paid	(10,321,675)	(8,640,953)
Net Cash Generated/(Used) from Operating Activities	527,305,846	356,826,908
B. Cash Flows from Investing Activities :		
Acquisition of Property, Plant & Equipment	(3,970,616)	(13,745,168)
Capital Work in Progress	(727,177,801)	(1,192,666,441)
Investment in Subsidiaries, Associate & Others	(28,008,489)	(184,197,960)
Interest, Dividend & Other Income	12,791,669	432,941
Net Cash Received/(Used) from Investing Activities	(746,365,237)	(1,390,176,629)
C. Cash Flows from Financing Activities :		
Long Term Loan Received/ (Repaid)	1,625,363,468	985,546,743
Short Term Loan Received/ (Repaid)	30,415,360	(2,620,446)
Lease obligation	(10,039,987)	(9,774,323)
Financial expenses paid	(67,798,474)	(21,134,467)
Dividend paid	(145,109)	(1,135,253)
Net Cash Received/(Used) from Financing Activities	1,577,795,257	950,882,254
Net Increase /(Decrease) in Cash & Cash Equivalents (A+B+C)	1,358,735,866	(82,467,466)
Cash & Cash Equivalents at the beginning of the period	106,134,829	414,994,148
Cash & Cash Equivalents at the end of the period	1,464,870,695	332,526,681
Number of Shares Used to Compute NOCFPS	234,000,000	234,000,000
Net Operating Cash Flow Per Share	2.25	1.52

34.1


Chairman


Managing Director


Director


Chief Financial Officer


Company Secretary

ORION PHARMA LIMITED
Condensed Statement of Cash Flows (Unaudited)
For Three Month Period Ended 30 September 2022

Particulars	Amount In BDT	
	July 2022 to September 2022	July 2021 to September 2021
A. Cash Flows from Operating Activities :		
Cash Received from Customers	736,426,717	673,615,613
Cash paid to Suppliers	(788,693,027)	(300,430,278)
Cash Payment for Operating Expenses	84,807,109	5,468,502
Cash Generated from Operation	32,540,799	378,653,836
Income Taxes Paid	(10,321,675)	(8,640,953)
Net Cash Generated/(Used) from Operating Activities	22,219,124	370,012,884
B. Cash Flows from Investing Activities :		
Acquisition of Property, Plant & Equipment	(3,296,066)	(13,504,268)
Capital Work in Progress	(727,177,801)	(1,192,666,441)
Investment in Subsidiaries, Associate, Securities & Others	(28,008,489)	(184,197,960)
Interest, Dividend & Other Income	12,791,670	432,941
Net Cash Received/(Used) from Investing Activities	(745,690,686)	(1,389,935,729)
C. Cash Flows from Financing Activities :		
Long Term Loan Received/ (Repaid)	2,068,416,431	1,024,071,254
Short Term Loan Received/ (Repaid)	(2,580,508)	(2,537,604)
Lease obligation	(10,039,987)	(9,774,323)
Dividend paid	(145,109)	(1,135,253)
Interest Paid	(20,267,339)	(19,404,160)
Net Cash Received/(Used) from Financing Activities	2,035,383,488	991,219,914
Net Increase /(Decrease) in Cash & Cash Equivalents (A+B+C)	1,311,911,926	(28,702,931)
Cash & Cash Equivalents at the beginning of the period	90,413,630	200,606,704
Cash & Cash Equivalents at the end of the period	1,402,325,554	171,903,772
Number of Shares Used to Compute NOCFPS	234,000,000	234,000,000
Net Operating Cash Flow Per Share	0.09	1.58


Chairman


Managing Director


Director


Chief Financial Officer


Company Secretary

ORION PHARMA LIMITED AND ITS SUBSIDIARIES
Selected Explanatory Notes to the Condensed Consolidated Financial Statements
For Three Month Period Ended 30 September 2022 (First Quarter)

1 Reporting Entity

1.1 Background of the Entity

Orion Pharma Limited, earlier called Orion Laboratories Limited was incorporated in 1965 as a private limited company. The Company was converted into a public limited company on 24 July 2010. The registered office of the company is at 153-154, Tejgaon I/A, Dhaka-1208, Bangladesh.

The Company is listed both with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE) on 20 March 2013.

1.2 Nature of Business

Orion Pharma Limited is engaged in the creation and discovery, development, manufacturing and marketing of pharmaceutical products including vaccines and health-related consumer products.

1.3 Subsidiary Companies

1.3.1 Orion Power Meghnaghat Limited

Orion Power Meghnaghat Ltd. was incorporated on 30 June 2010 as a public limited company under the Companies Act, 1994 with authorized share capital of Tk. 4,000,000,000 divided into 400,000,000 Ordinary shares of Tk. 10 each. The company implemented a 100 MW HFO Power based Plant on quick rental basis in Meghnaghat, Dhaka to supply electricity to national grid with machineries and equipment supplied by Wartsila OY, Finland. Orion Pharma Ltd. holds 95% of equity share of this company directly.

The company has signed the contract with Bangladesh Power Development Board (hereinafter referred as BPDB) acting as an off taker to supply power to them solely under the contract No. 09755 executed on June 30, 2010. According to the said contract, the Government will purchase the power for a period of five (5) years commencing from May 08, 2011. The contract has been extended for further five (5) years effective from May 09, 2016 vide memo no- 27.00.0000.071.14.035.2013.535 dated 01 December 2016. The contract then expired on 07 May 2021. The government renewed the contract for two (2) years effective from 24 March 2022 vide memo no – 27.11.0000.101.14.020.22-1697 dated: 10 April 2022. The purpose of this contract is to supply of Net Energy Output, under the terms and conditions provided “No Electricity, No Payment and also without any guaranteed Minimum Off-take” basis by Rental Power Company by BPDB.

1.3.2 Dutch Bangla Power & Associates Limited

Dutch Bangla Power & Associates Ltd. was incorporated on 1 July 2010 as a public limited company under the Companies Act, 1994 with authorized share capital of Tk. 1,000,000,000 divided into 100,000,000 ordinary shares of Tk. 10 each. The Company was awarded by the Government of Bangladesh and BPDB to implement 100 MW HFO Power Plant on quick rental basis in Siddhirganj, Narayanganj to supply electricity to national grid with machineries and equipment supplied by Wartsila OY, Finland. Orion Pharma Ltd. holds 67% of equity share of this Company.

The company has signed the contract with Bangladesh Power Development Board (hereinafter referred as BPDB) acting as an off taker to supply power to them solely under the contract No. 09756 executed on July 01, 2010. According to the said contract, the Government will purchase the power for a period of five (5) years commencing from July 21, 2011. The contract has been extended for further five (5) years effective from 22 July 2016 vide memo no- 27.00.0000.071.14.122.2010.534 dated 01 December 2016. The contract then expired on 22 July 2021. The government renewed the contract for two (2) years effective from 24 March 2022 vide memo no - 27.11.0000.101.14.020.22-1696 dated: 10 April 2022. The purpose of this contract is to supply of Net Energy Output, under the terms and conditions provided “No Electricity, No Payment and also without any guaranteed Minimum Off-take” basis by Rental Power Company by BPDB.

1.4 Associate Company

Orion Infusion Limited

Orion Infusion Limited is a public limited company incorporated in Bangladesh on May 05, 1983 and is now operating under the banner of Orion Group. Other shareholders of the company are sponsor shareholders, foreign investors, financial institutions and general public.

The Company was listed with Dhaka Stock Exchange Limited (DSE) on 05 October 1994 and Chittagong Stock Exchange Limited (CSE) on 22 September 1996. Orion Pharma Ltd. holds 21.76 % of equity share of this company directly.

2 Basis of Preparation

2.1 Statement of Compliance

These Condensed Interim Financial Statements of the company comprised the company's and its subsidiaries (together referred to as the 'Group' and individually as 'Group entities') and the Group's interest in associates have been prepared in accordance with International Financial Reporting Standards (IFRSs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB), in particular International Accounting Standard (IAS) 34: *Interim Financial Reporting*, the Companies Act 1994, Securities and Exchange Rules 1987 and other applicable laws and regulations.

2.2 Components of the Condensed Financial Statements

According to IAS-34 'Interim Financial Reporting', these interim financial statements include the following components-

- Condensed Consolidated Statement of Financial Position
- Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income
- Condensed Consolidated Statement of Changes in Equity
- Condensed Consolidated Statement of Cash Flows
- Selected Explanatory Notes to the Condensed Consolidated Financial Statements

2.3 Basis of Measurement

The financial statements have been prepared on historical cost basis except for certain assets which are stated either at revalued amount or fair market value.

2.4 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Taka (Taka/Tk./BDT), which is the company's functional and presentation currency. All amounts have been rounded off to the nearest integer.

2.5 Reporting Period

These Condensed Interim Financial Statements of the company cover three month period from 1 July 2022 to 30 September 2022.

2.6 Date of Authorization

The financial statements were authorized for issue by the Board of Directors in its meeting held on November 14, 2022 for publication.

2.7 Events after the reporting period

Information regarding subsidiary companies

For this quarter there was no such issue.

3 Accounting Policies and Methods of Computations

The accounting policies and methods of computations followed in preparing these financial statements are same as those used in the annual financial statements prepared and published for the year ended 30 June 2022.

4 Subsequent Events

No material events occurred after the reporting date, non-disclosure of which could affect the ability of the users of the financial statements to make proper evaluation and decision.

5 Acquisition of Property, Plant & Equipments of Orion Pharma Ltd. and its subsidiaries during the Period.

Discloser as per BSEC Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018.

SL No.	Particulars	Amount in BDT	
		30-Sep-22	30-Sep-21
i	Land & Land Development	-	-
ii	Factory & Office Building	-	-
iii	Plant & Machinery	7,500	-
iv	Furniture & Fixtures	247,570	7,526,224
v	Office Equipment	3,715,546	5,913,080
	Total	3,970,616	13,439,304

SL No.	Particulars	Amount in BDT			
		30-Sep-22	30-Jun-22		
6.	Property, plant and equipment				
	Opening balance	13,826,413,931	14,219,821,108		
	Add: Addition during the year	3,970,617	83,427,459		
	Less: Sale /disposal during the year	-	(4,000,100)		
		13,830,384,547	14,299,248,466		
	Less: Depreciation charged during the year	(155,644,832)	(472,834,536)		
	Written down value	13,674,739,714	13,826,413,931		
6a.	Property, plant and equipment				
	Opening balance	7,449,132,157	7,746,013,649		
	Add: Addition during the year	3,296,066	82,838,815		
	Less: Sale /disposal during the year	-	(4,000,100)		
		7,452,428,223	7,824,852,364		
	Less: Depreciation charged during the year	(82,649,962)	(375,720,207)		
	Written down value	7,369,778,261	7,449,132,157		
7.	Right of use assets				
	Opening Balance	130,974,449	106,698,236		
	Add: Addition during the year	-	24,276,213		
		130,974,449	130,974,449		
	Less: Disposal/ adjustment	-	-		
		130,974,449	130,974,449		
	Amortization				
	Opening balance	81,500,510	55,886,807		
	Addition during the year	6,036,462	25,613,703		
		87,536,972	81,500,510		
	Written down value	43,437,477	49,473,939		
8.	Construction work in progress				
	Opening balance	9,133,148,194	5,584,939,176		
	Add: Addition during the year	727,177,801	3,548,209,017		
		9,860,325,995	9,133,148,194		
9.	Investment in subsidiaries				
	Name of the subsidiary company	Number of shares	Share holding (%)	Amount in BDT	
				30-Sep-22	30-Jun-22
	Orion Power Meghnaghat Ltd.	95,000,000	95.00	950,000,000	950,000,000
	Dutch Bangla Power & Associates L	6,700,000	67.00	67,000,000	67,000,000
	Total			1,017,000,000	1,017,000,000
Investment in subsidiaries are stated at cost.					
10.	Investment in associate				
	Orion Infusion Limited				
	Opening balance			386,739,000	303,455,000
	Add: Share of profit during the year			2,790,900	9,303,000
	Less: Dividend during the year			-	(4,430,000)
	Add: Share of other comprehensive income			(207,652)	245,284
	Add: Fair value adjustment			2,198,240,752	78,165,716
				2,587,563,000	386,739,000

SL No.	Particulars	Amount in BDT	
		30-Sep-22	30-Jun-22
11. Other investment			
	Investment in marketable securities (Note 11.1)	34,576,533	34,952,635
	Investment in non-Quoted Shares (Note 11.2)	5,921,740,676	5,921,740,676
		5,956,317,209	5,956,693,311
11.1 Investment in marketable securities			
	AB Investment Limited.	19,207,548	17,758,600
	Bank Asia Securities Limited.	6,711,195	7,426,205
	LankaBangla Securities Ltd.	8,657,790	9,767,830
		34,576,533	34,952,635
11.2 Investment in non-quoted shares			
	Orion Power Khulna Limited.	500,000	500,000
	Orion Power Dhaka Limited.	500,000	500,000
	ICB Islami Bank Limited	246,000	246,000
	Orion Infrastructure Limited.	2,117,209,676	2,117,209,676
	Energon Renewable (BD) Ltd.	1,500,000	1,500,000
	Orion Power Unit - 2 Dhaka Ltd.	3,801,785,000	3,801,785,000
		5,921,740,676	5,921,740,676
11a Other investment			
	Investment in marketable securities (Note 11a.1)	34,576,533	34,952,635
	Investment in non-Quoted Shares (Note 11a.2)	2,120,240,676	2,120,240,676
		2,154,817,209	2,155,193,311
11a.1 Investment in marketable securities			
	AB Investment Limited.	19,207,548	17,758,600
	Bank Asia Securities Limited.	6,711,195	7,426,205
	LankaBangla Securities Ltd.	8,657,790	9,767,830
		34,576,533	34,952,635
11a.2 Investment in non-quoted shares			
	Orion Power Khulna Limited.	500,000	500,000
	Orion Power Dhaka Limited.	500,000	500,000
	ICB Islami Bank Limited	246,000	246,000
	Orion Infrastructure Limited.	2,117,209,676	2,117,209,676
	Orion Power Unit - 2 Dhaka Ltd.	1,785,000	1,785,000
		2,120,240,676	2,120,240,676
12. Inventories			
	Raw materials	348,903,276	336,815,123
	Packing materials	121,570,453	101,676,205
	Work-in-process	39,536,250	26,026,206
	Finished goods	87,032,294	120,192,373
	Printing Stationeries	15,571,630	17,082,726
	Promotional materials	2,114,642	12,040,492
	Import related expenses	734,225,729	721,816,897
	Spare parts	587,347,347	601,362,242
	Inventory HFO & LFO	384,779,193	408,653,749
		2,321,080,813	2,345,666,013
12.a Inventories			
	Raw materials	348,903,276	336,815,123
	Packing materials	121,570,453	101,676,205
	Work-in-process	39,536,250	26,026,206
	Finished goods	87,032,294	120,192,373
	Printing Stationeries	15,571,630	17,082,726
	Promotional materials	2,114,642	12,040,492
	Import related expenses	703,240,502	717,955,388
		1,317,969,046	1,331,788,513

SL No.	Particulars	Amount in BDT	
		30-Sep-22	30-Jun-22
13. Trade & other receivables			
	Trade receivables	9,932,038,978	6,796,180,596
	Other receivables (Note-13.1)	8,375,462,811	8,109,160,151
		18,307,501,789	14,905,340,747

Trade receivables are unsecured, considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

Ageing of the above balance is as follows:

Below 180 days	9,932,038,978	6,796,180,596
Above 180 days	-	-
	9,932,038,978	6,796,180,596

SL. No.	Particulars	Amount in BDT	
		30-Sep-22	30-Jun-22
I	Trade receivables considered good in respect of which the company is fully secured	9,932,038,978	6,796,180,596
II	Trade receivables considered good in respect of which the company holds no security other than the debtor personal security	-	-
III	Trade receivables considered doubtful or bad	-	-
IV	Trade receivables due by any director or other officer of the company	-	-
V	Trade receivables due by common management	-	-
VI	The maximum amount of receivable due by any director or other officer of the company	-	-
	Total	9,932,038,978	6,796,180,596

13.1 Other receivables

Claim receivables, insurance & others	3,808,114	6,035,905
Dividend receivable	-	4,430,000
Interest on FDR	356,297	522,317
Other receivables	1,450,194,088	1,230,374,877
Current account with other related companies (Note. 13.1.1)	6,921,104,312	6,867,797,052
	8,375,462,811	8,109,160,151

13.1.1 Current account with other related companies

Noakhali Gold Food Ltd.	10,859,928	10,859,928
Orion Properties Ltd.	22,101,089	22,101,089
Orion Gas Limited	83,988,384	83,988,384
Orion Power Khulna Ltd.	986,021,913	986,021,913
Orion Power Dhaka Ltd.	2,262,265,128	2,262,265,128
Jafflong Tea Company	2,408,371	2,408,371
Orion Agro Product	251,418,758	251,418,758
Interior Accom Consortium Limited	74,629,265	74,629,265
Digital Power & Associate Ltd.	765,798,201	764,666,015
Orion Footwear Ltd.	162,162,162	122,162,162
Panbo Bangla Mashroom Ltd.	32,500,000	32,500,000
Orion Power Unit 2 Dhaka Ltd.	855,394,296	1,062,410,312
Orion Home Appliance Ltd.	117,807,496	117,807,496
Orion Hospitals Ltd.	22,700,000	22,700,000
Orion Power Rupsha Ltd.	82,722,069	82,722,069
Energon Renewable (BD) Ltd.	642,717,731	618,527,731
Orion Quaderia Textiles Limited	130,000,000	130,000,000
Orion Tea Company Ltd	232,373,431	141,823,431
Orion Natural Care Ltd.	78,785,000	78,785,000
Orion Power Sonargaon Ltd	104,451,091	
	6,921,104,312	6,867,797,052

SL No.	Particulars	Amount in BDT	
		30-Sep-22	30-Jun-22
13.a	Trade & other receivables		
	Trade receivables	179,446,501	181,873,519
	Other receivables (Note - 13a.1)	7,645,780,178	7,618,285,687
		7,825,226,679	7,800,159,206

Trade receivables are unsecured, considered good and recoverable within one year. Classification schedules as required by schedule XI of Companies Act 1994 are as follows:

Ageing of the above balance is as follows:

Below 180 days	179,446,501	181,873,519
Above 180 days	-	-
	179,446,501	181,873,519

SL No	Particulars	Amount in BDT	
		30-Sep-22	30-Jun-22
I	Trade receivables considered good in respect of which the company is fully	179,446,501	181,873,519
II	Trade receivables considered good in respect of which the company holds no security other than the debtor personal security		-
III	Trade receivables considered doubtful or bad		-
IV	Trade receivables due by any director or other officer of the company		-
V	Trade receivables due by common management		-
VI	The maximum amount of receivable due by any director or other officer of the		-
	Total	179,446,501	181,873,519

13a.1 Other receivables

Claim receivables, insurance & others	3,808,114	6,035,905
Dividend receivable	-	4,430,000
Interest on FDR	356,297	522,317
Other receivables	1,230,374,877	1,230,374,877
Current account with subsidiaries (13a.1.1)	372,395,908	372,395,908
Current account with other related companies (13a.1.2)	6,038,844,982	6,004,526,680
	7,645,780,178	7,618,285,687

13a.1.1 Current account with subsidiaries

Dutch Bangla Power & Associates Limited.	372,395,908	372,395,908
	372,395,908	372,395,908

13a.1.2 Current account with other related companies

Orion Properties Ltd.	20,331,532	20,331,532
Orion Power Khulna Ltd.	986,021,913	986,021,913
Orion Power Dhaka Ltd.	2,176,336,879	2,176,336,879
Interior Accom Consortium Ltd.	107,786,265	107,786,265
Orion Agro Product Ltd.	243,565,920	243,565,920
Orion Power Unit -2 Dhaka Ltd.	965,542,114	1,172,348,130
Orion Power Rupsha Ltd.	3,300,000	3,300,000
Digital Power & Associates Ltd.	181,911,496	181,911,496
Orion Hospitals Ltd.	17,700,000	17,700,000
Energion Renewables (BD) Ltd.	658,017,731	633,827,731
Orion Home Appliances Ltd.	110,000,000	110,000,000
Orion Natural Care Ltd.	78,785,000	78,785,000
Orion Gas Ltd.	34,788,384	34,788,384
Panbo Bangla Mushroom Ltd	32,500,000	32,500,000
Orion Footwear Ltd.	53,500,000	13,500,000
Orion Tea Company Ltd	232,373,431	141,823,431
Orion Power Sonargaon Ltd	136,384,318	50,000,000
	6,038,844,982	6,004,526,680

SL No.	Particulars	Amount in BDT	
		30-Sep-22	30-Jun-22
14.	Advances, deposits and prepayments		
	Advances:		
	Advance income tax (Note-14.1)	220,768,373	210,375,679
	Advance imprest money	113,500	117,500
	Advance motor cycle	6,850,822	7,969,236
	Advance - car loan	1,121,929	1,255,264
	Collection advance	9,591,633	8,172,329
	Advance to C&F agents	8,307,774	336,261
	Advance office rent	4,727,035	5,167,798
	Advance against land purchase	117,260,635	87,260,635
	Advance for Impoted machinery	216,845,470	-
	Advance to employee	116,030,539	118,122,720
	Other advance	94,206	219,913,417
	Advance Cash Purchase		2,640,629
	Advance to Supplier	211,779,466	148,455,963
		913,491,382	809,787,431
	Deposits:		
	Earnest money	9,781,938	9,781,938
	Security deposit	46,080,285	45,222,118
	Bank guarantee	76,768,676	113,618,843
	L/C Margin & Balance	287,218,903	358,461,999
	Lease deposit	2,293,027	2,530,527
		422,142,829	529,615,425
	Prepayments:		
	Insurance premium	299,559	262,995
	Bank gurantee,commission & charge	13,799,177	25,929,644
		14,098,736	26,192,639
		1,349,732,947	1,365,595,495
14.1	Advance income tax		
	Opening balance	210,375,679	166,583,988
	Add: Addition during the year	10,392,694	43,791,691
		220,768,373	210,375,679
	Less: Adjustment of assessment for previous	-	-
	Closing balance	220,768,373	210,375,679
14.a	Advances, deposits & prepayments		
	Advances:		
	Advance income tax (Note -14a.1)	218,967,091	208,645,416
	Advance imprest money	113,500	117,500
	Motor cycle advance	6,850,822	7,969,236
	Advance - car loan	1,121,929	1,255,264
	Collection advance	9,591,633	8,172,329
	Advance to C&F agents	8,307,774	336,261
	Advance office rent	4,727,035	5,167,798
	Advance against land purchase	117,260,635	87,260,635
	Advance for machinery - BHF Bank	216,845,470	-
	Advance to Employee	107,053,145	108,855,027
	Others Advance	94,206	94,206
	Advance Cash Purchase	-	2,640,629
	Advance Paid to Suppliers	184,781,085	128,492,306
		875,714,325	559,006,606

SL No.	Particulars	Amount in BDT	
		30-Sep-22	30-Jun-22
	Deposits		
	Earnest money	9,781,938	9,781,938
	Security deposit	46,080,285	45,222,118
	Bank guarantee	-	848,167
	Lease deposit	2,293,027	2,293,027
	L/C Margin & Balance	127,700,000	198,943,096
		185,855,250	257,088,346
		1,061,569,575	816,094,952
14a.1	Advance income tax		
	Opening balance	208,645,416	165,028,566
	Addition during the year	10,321,675	43,616,850
	Closing balance	218,967,091	208,645,416
15.	Fixed deposit with banks		
	Social Islami Bank Limited., Principal Branch, Dhaka.	9,521,255	9,409,892
	Agrani Bank Ltd.	22,826,333	22,423,697
		32,347,588	31,833,589
16.	Cash & cash equivalents		
	Cash in hand (Note -16.1)	15,759,959	14,677,215
	Cash at B/O account (Note -16.2)	10,806	11,956
		15,770,764	14,689,171
	Balance with banks on account		
	Current account	1,440,162,877	87,105,053
	Short term deposit account	8,937,054	4,340,604
		1,449,099,931	91,445,657
		1,464,870,695	106,134,828
16.1	Cash in hand		
	Head office	6,186,994	5,996,261
	Depot office	9,572,965	8,680,954
		15,759,959	14,677,215
16.2	Cash at B/O account		
	Bank Asia Securities Limited.	5,878	6,328
	Jahan Securities Limited.	1,524	1,974
	LankaBangla Securities Ltd.	3,404	3,654
		10,806	11,956
16.a	Cash and cash equivalents		
	Cash in hand (Note -16a.1)	12,221,396	12,041,644
	Cash at B/O account (Note -16a.2)	10,806	11,956
		12,232,201	12,053,600
	Cash at Bank:		
	Current account	1,381,156,299	74,019,426
	Short term deposit account	8,937,054	4,340,604
		1,390,093,353	78,360,030
		1,402,325,554	90,413,630
16a.1	Cash in hand		
	Head office - central cash & main cash	4,234,352	4,914,168
	Depot office - petty cash	7,987,044	7,127,476
		12,221,396	12,041,644

SL No.	Particulars	Amount in BDT	
		30-Sep-22	30-Jun-22
16a.2	Cash at B/O account		
	Bank Asia Securities Limited	5,878	6,328
	Jahan Securities Limited	1,524	1,974
	LankaBangla Securities Ltd.	3,404	3,654
		10,806	11,956

17. Share capital

Authorized capital

500,000,000 ordinary shares of Tk. 10 each

5,000,000,000 **5,000,000,000**

Issued, subscribed and paid-up capital

234,000,000 ordinary shares of Tk. 10 each

2,340,000,000 **2,340,000,000**

Shareholding position of the company

Range of Shareholding	Number of Shareholders	Number of Shares	% of holding	
			30-Sep-22	30-Jun-22
Up to 500 Shares	24,895	3,524,859	1.51%	1.37%
501 to 5,000 Shares	8,688	16,255,055	6.95%	5.49%
5001 to 10,000 Shares	1,426	10,567,422	4.52%	3.70%
10,001 to 20,000 Shares	858	12,478,738	5.33%	3.95%
20,001 to above	977	191,173,926	81.70%	85.49%
Total	36,844	234000000	100%	100%

Categories of shareholders	Number of Shareholders	Number of Shares	% of holding	
			30-Sep-22	30-Jun-22
Sponsors	5	74,841,600	31.98%	31.98%
Foreign Investor	365	2,747,129	1.17%	1.16%
Financial institutions	687	59,257,640	25.32%	28.65%
General public	35,787	97,153,631	41.52%	38.21%
Total	36,844	234000000	100%	100%

Orion Power Meghnaghat Limited	Number of Shares	Face Value	% of holding	
			30-Sep-22	30-Jun-22
Orion Pharma Limited	95,000,000	950,000,000	95.00%	95.00%
Integral Energy Limited	3,000,000	30,000,000	3.00%	3.00%
Jafflong Tea Company Limited	500,000	5,000,000	0.50%	0.50%
Mr. Mohammad Obaidul Karim	500,000	5,000,000	0.50%	0.50%
Mr. Salman Obaidul Karim	600,000	6,000,000	0.60%	0.60%
Mrs. Arzuda Karim	350,000	3,500,000	0.35%	0.35%
Haarhuis Generation B.V.	50,000	500,000	0.05%	0.05%
Total	100,000,000	1,000,000,000	100%	100%

Dutch Bangla Power & Associates Limited	Number of Shares	Face Value	% of holding	
			30-Sep-22	30-Jun-22
Orion Pharma Limited	6,700,000	67,000,000	67.00%	67.00%
Shenzhen Nanshan Power Co. Ltd.	50,000	500,000	0.50%	0.50%
Mohammad Obaidul Karim	100,000	1,000,000	1.00%	1.00%
Salman Obaidul Karim	3,087,500	30,875,000	30.88%	30.88%
Orion Tea Company Ltd.	50,000	500,000	0.50%	0.50%
Jafflong Tea Co. Ltd.	2,500	25,000	0.03%	0.03%
Mrs. Arzuda Karim	10,000	100,000	0.10%	0.10%
Total	10,000,000	100,000,000	100%	100%

SL No.	Particulars	Amount in BDT	
		30-Sep-22	30-Jun-22
18. Reserves			
	Fair value gain/(loss) on investment in associate (Note -18.1)	2,495,348,237	297,107,485
	Fair value gain/(loss) on marketable securities (Note -18.2)	(7,574,046)	(7,235,554)
	Share of other comprehensive income of associate (Note - 18.3)	6,432,833	6,640,485
	Revaluation surplus on property, plant and equipment (Note -18.4)	1,677,899,810	1,681,581,746
		4,172,106,833	1,978,094,161
18.1 Fair value gain on investment in associate			
	Opening balance	297,107,485	218,941,769
	Fair value gain/ (loss) during the year	2,198,240,752	78,165,716
		2,495,348,237	297,107,485
18.2 Fair value gain/(loss) on marketable securities			
	Opening balance	(7,235,554)	(12,027,113)
	Adjustment of sale of marketable securities	1,350	(78,114)
	Fair value gain/(loss) on marketable securities (Note - 18.2.1)	(377,452)	5,402,068
	Transferred to deferred tax assets/(liabilities)	37,610	(532,395)
		(7,574,046)	(7,235,554)
18.2.1 Fair value gain/(loss) on marketable securities during the year			
	Unrealized gain/(loss) position (closing)	(8,415,606)	(8,039,504)
	Unrealized gain/(loss) position (opening)	(8,039,504)	(13,363,458)
	Total change during the year	(376,102)	5,323,954
	Fair value adjustment for sale of securities (realized loss)	(1,350)	78,114
	Unrealized gain/(loss) during the year	(377,452)	5,402,068
18.3 Share of other comprehensive income			
	Opening balance	6,640,485	6,395,201
	Add: Addition during the year	(207,652)	245,284
		6,432,833	6,640,485
18.4 Revaluation surplus on property, plant & equipment			
	Opening balance	1,681,581,746	1,691,542,515
	Adjustment during the year to retained earnings for depreciation	(3,970,285)	(11,263,959)
	Adjustment of deferred tax on revaluation surplus	288,349	1,303,189
		1,677,899,810	1,681,581,746
18.a Reserve			
	Fair value gain on investment in associates (Note - 18a.1)	2,495,348,237	297,107,485
	Fair value gain/(loss) on marketable securities (Note - 18a.2)	(7,574,045)	(7,235,554)
	Share of other comprehensive income (Note - 18a.3)	6,432,833	6,640,485
	Revaluation surplus on property, plant & equipment (Note - 18a.4)	1,314,476,894	1,316,110,872
		3,808,683,918	1,612,623,288
18a.1 Fair value gain on investment in associates			
	Opening balance	297,107,485	218,941,769
	Fair value gain/(loss) during the year	2,198,240,752	78,165,716
		2,495,348,237	297,107,485

SL No.	Particulars	Amount in BDT	
		30-Sep-22	30-Jun-22
18a.2	Fair value gain/(loss) on marketable securities		
	Opening balance	(7,235,554)	(12,027,112)
	Adjustment of sale of marketable securities	1,350	(78,114)
	Fair value gain/(loss) on marketable securities D/Y (Note - 18a.2.1)	(377,452)	5,402,068
	Transferred to deferred tax assets/(liabilities)	37,610	(532,395)
		(7,574,045)	(7,235,554)
18a.2.1	Fair value gain/(loss) on marketable securities during the year		
	Unrealized gain/(loss) position (closing)	(8,415,606)	(8,039,504)
	Unrealized gain/(loss) position (opening)	(8,039,504)	(13,363,458)
	Fair value adjustment for sale of securities realized	(1,350)	78,114
	Unrealized gain/(loss) during the year	(377,452)	5,402,068
18a.3	Share of other comprehensive income		
	Opening balance	6,640,485	6,395,201
	Add: Addition during the year	(207,652)	245,284
		6,432,833	6,640,485
18a.4	Revaluation surplus on property, plant & equipment		
	Opening balance	1,316,110,872	1,323,495,609
	Adjustment during the year to retained earnings for depreciation	(1,922,327)	(8,687,926)
	Adjustment of deferred tax on revaluation surplus	288,349	1,303,189
		1,314,476,894	1,316,110,872
19.	Retained earnings		
	Opening balance	6,977,538,555	6,400,990,484
	Net profit after tax	169,375,631	846,084,112
	Dividend for the year	-	(280,800,000)
	Adjustment for depreciation on revaluation surplus	3,970,285	11,263,959
		7,150,884,472	6,977,538,555
19.a	Retained Earnings		
	Opening balance	909,063,184	518,496,227
	Net profit after tax	99,705,268	662,679,032
	Dividend for the year	-	(280,800,000)
	Adjustment for depreciation on revaluation surplus	1,922,327	8,687,926
		1,010,690,779	909,063,184
20.	Non-controlling interest		
	Opening balance	1,456,338,901	1,411,671,307
	Share of operating profit	5,890,313	44,667,594
	Closing balance	1,462,229,214	1,456,338,901
21	Syndicated loan and other long term loans		
	Mashreq bank PSC	1,863,990,382	2,307,043,344
	Phoenix Finance & Investment Ltd.	140,649,799	161,931,838
	Agrani Bank Ltd. -BMRE	4,008,567,585	3,918,443,387
	Social Islami Bank Ltd	1,285,749,418	1,612,210,873
	Term Loan -SBLC Agrani Bank Ltd	2,536,109,550	2,536,109,550
	Term Loan Capital Machinery - UPAS L/C	2,160,954,336	2,371,734,657
	AL-Arafa Islami Bank Ltd.	2,000,104,803	2,028,666,719
	ODDO BHF AG Finance	814,318,841	814,318,841
	Rupali Bank Ltd.	2,296,279,800	2,237,579,186
	Janata Bank Ltd	2,506,677,350	-
		19,613,401,864	17,988,038,395
	Less: Current portion of long term loan (Note 21.1)	(408,151,600)	(387,466,840)
		19,205,250,264	17,600,571,555

SL No.	Particulars	Amount in BDT	
		30-Sep-22	30-Jun-22
21.1	Current portion of long term loan		
	Phoenix Finance & Investment Ltd.	82,424,064	61,739,304
	ODDO BHF AG Finance	325,727,536	325,727,536
		408,151,600	387,466,840
21.a	Long term loan		
	Phoenix Finance & Investment Ltd.	140,649,799	161,931,838
	Agrani Bank Ltd. -BMRE	4,008,567,585	3,918,443,387
	Social Islami Bank Ltd.	1,285,749,418	1,612,210,873
	Term Loan -SBLC Agrani Bank Ltd.	2,536,109,550	2,536,109,550
	Term Loan Capital Machinery - UPAS L/C	2,160,954,336	2,371,734,657
	AL-Arafa Islami Bank Ltd.	2,000,104,803	2,028,666,719
	ODDO BHF AG Finance	814,318,841	814,318,841
	Rupali Bank Ltd.	2,296,279,800	2,237,579,186
	Janata Bank Ltd	2,506,677,350	-
		17,749,411,482	15,680,995,051
	Less: Current portion of long term loan (Note 21.a.1)	(408,151,600)	(387,466,840)
		17,341,259,882	15,293,528,211
21.a.1	Current portion long term loan		
	Phoenix Finance & Investment Ltd.	82,424,064	61,739,304
	ODDO BHF AG Finance	325,727,536	325,727,536
		408,151,600	387,466,840
22	Lease obligation		
	Phoenix Finance & Investment Ltd.	9,382,480	13,324,838
	Lease obligation (Office rent)	47,507,232	53,604,861
		56,889,712	66,929,699
	Current portion of lease obligation (22.1)	(24,313,106)	(31,664,304)
		32,576,606	35,265,395
22.1	Current portion of lease obligation		
	Phoenix Finance & Investment Ltd.	8,306,580	13,035,912
	Lease obligation (Office rent)	16,006,526	18,628,392
		24,313,106	31,664,304
23	Deferred tax liability		
	Opening balance	122,246,456	138,284,281
	Adjustment for deferred tax expenses /(income) (Note-23.1)	9,854,278	(15,267,031)
	Adjustment for deferred tax on revaluation surplus (Note-23.2)	(325,959)	(770,794)
		131,774,776	122,246,457
23.1	Adjustment during the year on deferred tax on PPE		
	Deferred tax liability on PPE (closing)	83,512,373	73,658,095
	Deferred tax liability on PPE (opening)	73,658,095	88,925,125
	Deferred tax expenses/(income)	9,854,278	(15,267,031)

Particular	WDV as at 30.09.2022		Amount in BDT	
	Tax Base	Accounting Base	Deferred Tax Liability as on 30.09.2022	Deferred Tax Liability as on 30.06.2022
Written down value of property, plant and equipment	2,793,577,268	3,164,743,371	(83,512,373)	(73,658,095)

SL No.	Particulars	Amount in BDT	
		30-Sep-22	30-Jun-22
23.2	Adjustment of deferred tax on revaluation Surplus		
	Deferred tax liability on revaluation surplus (Closing) (Note-23.2.1)	48,262,402	48,588,362
	Deferred tax liability on revaluation surplus (Opening)	48,588,362	49,359,155
	Deferred tax expenses/(income)	(325,959)	(770,794)

23.2.1 Adjustment of deferred tax on revaluation surplus

Particulars	WDV as at 30.09.2022		Amount in BDT	
	Tax Base	Accounting Base	Deferred Tax Liability as on 30.09.2022	Deferred Tax Liability as on 30.06.2022
Revaluation reserved on land & land development	-	1,298,728,729	(38,961,862)	(38,961,862)
Revaluation reserved factory & office building	-	53,452,267	(8,017,840)	(8,223,426)
Revaluation reserved plant & machinery	-	14,161,741	(2,124,261)	(2,207,025)
Revaluation reserve on marketable securities	-	(8,415,606)	841,561	803,950
Total	-	1,357,927,131	(48,262,402)	(48,588,362)

24. Shot term loans

Cash credit (Hypo) Agrani Bank Ltd.	357,741,883	357,789,664
LTR Agrani Bank Ltd., WASA Corporate Branch	138,386,433	140,712,060
Loan against marketable securities	65,195,445	65,402,545
	561,323,761	563,904,269

25 Trade and other payables

Goods suppliers & manufacturer	10,158,972,898	7,301,370,368
Other payable	258,517,928	278,874,271
Current account with inter companies (Note -25.1)	748,857,033	139,264,463
	11,166,347,858	7,719,509,102

25.1 Current account with inter companies

Orion Capital Ltd.	18,420,000	18,420,000
Orion Power Sonargaon Ltd.	78026115	25,933,315
Orion Oil & Shipping Ltd.	649,410,918	91,911,148
Orion Ship Management Ltd.	3,000,000	3,000,000
	748,857,033	139,264,463

25.a Trade and other payables

Goods suppliers & manufacturer	330,075,295	298,385,557
Other payables	70,250,134	91,958,842
	400,325,428	390,344,399

26 Employee benefits

Workers welfare fund (Note -26.1)	15,592,308	14,520,404
Bangladesh workers welfare foundation (Note -26.2)	21,170,778	20,098,874
Workers profit participation fund (Note -26.3)	103,860,547	96,769,338
	140,623,632	131,388,616

26.1 Workers welfare fund

Opening balance	14,520,404	11,104,537
Add: Addition for the year	1,071,904	5,270,806
Less: Payment during the year	-	(1,854,940)
	15,592,308	14,520,404

SL No.	Particulars	Amount in BDT	
		30-Sep-22	30-Jun-22
26.2	Bangladesh workers welfare foundation		
	Opening balance	20,098,874	14,828,067
	Add: Addition for the year	1,071,904	5,270,806
	Less: Payment during the year		
		21,170,778	20,098,874
26.3	Workers profit participation fund		
	Opening balance	96,769,338	71,297,346
	Add: Addition for the year	8,575,238	42,166,450
	Less: Payment during the year	(1,484,030)	(16,694,458)
		103,860,547	96,769,338
26.a	Employee benefits		
	Workers welfare fund (Note -26.a.1)	7,162,489	6,468,388
	Bangladesh workers welfare foundation (Note -26.a.2)	11,256,930	12,046,858
	Workers profit participation fund (Note -26.a.3)	37,906,027	32,353,216
		56,325,446	50,868,462
26.a.1	Workers welfare fund		
	Opening Balance	6,468,388	4,192,885
	Addition during the year	694,101	4,130,443
	Payment during the year	-	(1,854,940)
		7,162,489	6,468,388
26.a.2	Bangladesh workers welfare foundation		
	Opening balance	12,046,858	7,916,415
	Addition for the year	694,101	4,130,443
	Payment during the year	(1,484,030)	-
		11,256,930	12,046,858
26.a.3	Workers profit participation fund		
	Opening Balance	32,353,216	16,004,131
	Addition during the year	5,552,811	33,043,543
	Payment during the year	-	(16,694,458)
		37,906,027	32,353,216
WPPF is charged @ 5% of net profit before tax as per labour law Act 2006 (Amended in 2013), whereas 80% is allocated to "Workers profit participation fund", 10% to "Employee welfare fund" and 10% to "Bangladesh workers welfare foundation".			
27.	Accrued expenses		
	Salary and wages payable	91,467,487	88,775,113
	Director remuneration payable	12,394,994	10,627,316
	Depot expenses payable	2,498,938	300,000
	Telephone & mobile bill payable	4,352,368	5,719,829
	Payable for final settlement of employee	9,108,362	8,424,487
	Utilities payable	10,674,136	10,378,399
	Provision for income tax (Note 27.1)	430,666,789	398,615,158
	Corporate governance audit fees	69,000	69,000
	Statutory Audit fees	1,265,000	1,380,000
	Interest payable on Mashreq Dubai	8,869,722	8,346,572
	Retention money	3,618,657	3,618,657
	Provision for gratuity	21,905,998	22,307,848
	Interest payable on Phonix Finance and Investment Ltd.		30,008
	Withholding VAT	19,007,106	18,395,212
	Withholding tax	12,766,366	12,248,002
		628,664,923	589,235,603

SL No.	Particulars	Amount in BDT	
		30-Sep-22	30-Jun-22
27.1	Provision for income tax		
	Opening balance	398,615,158	262,748,141
	Add: Addition during the year	32,051,631	187,979,580
		430,666,789	450,727,721
	Less: Payment/AIT adjustment during the year	-	(52,112,563)
		430,666,789	398,615,158
27.a	Accrued expenses		
	Salary and wages payable	68,425,872	67,392,762
	Director remuneration payable	300,000	300,000
	Depot expenses payable	2,498,938	2,002,320
	Telephone & mobile bill payable	4,352,368	5,719,829
	Payable for final settlement of employee	9,108,362	8,424,487
	Utilities payable	10,674,136	10,378,399
	Provision for income tax (Note - 26.a.1)	430,666,789	398,615,158
	Corporate governance audit fees	69,000	690,000
	Statutory Audit fees	575,000	69,000
		526,670,465	493,591,956
27.a.1	Provision for income tax		
	Opening balance	398,615,158	262,748,140
	Add: Addition during the year	32,051,631	187,979,580
		430,666,789	450,727,721
	Less: Payment/AIT adjustment during the year	-	(52,112,563)
	Closing balance	430,666,789	398,615,158

SL No.	Particulars	Amount in BDT	
		July 2022 to September 2022	July 2021 to September 2021
28. Revenue from net sales			
Local sales		692,384,233	679,040,273
Export sales		41,615,467	28,999,021
Revenue from power generation (Note-28.1)		3,180,680,619	479,689,237
		3,914,680,319	1,187,728,531
28.1 Revenue from power generation			
Reference rental price		-	71,122,581
Reference energy price (variable - O&M)		545,575,741	11,840,341
HFO received from OOSL & BPDB		2,635,104,878	396,726,315
Foreign exchange gain /(loss)		-	-
		3,180,680,619	479,689,237
28.a Revenue from net sales			
Local sales		692,384,233	679,040,273
Export sales		41,615,467	28,999,021
		733,999,700	708,039,294
29 Financial expense			
Agrani Bank Limited, Cash Credit (Hypo.)		7,836,701	7,982,733
Agrani Bank Limited, LTR		3,184,452	3,307,727
Phoenix Finance & Investments Ltd.		5,933,493	7,059,067
Meridian Finance & Investment Ltd.		-	36,879
Finance cost on lease obligation (Office rent)		1,042,404	1,034,555
Bank Charge ,commission & Fees		14,816,586	1,713,507
Interest on Long Term Borrowing		36,322,583	27,878,868
		69,136,219	49,013,336
29a Financial expenses			
Agrani Bank Limited, Cash Credit (Hypo.)		7,836,701	7,982,733
Agrani Bank Limited, LTR		3,184,452	3,307,727
Phoenix Finance & Investments Ltd.		5,534,515	7,042,266
Meridian Finance & Investment Ltd.		-	36,879
Finance cost on lease obligation (Office rent)		1,042,404	1,034,555
Bank Commision, Fees, VAT and Other Charges		2,669,267	-
		20,267,339	19,404,160
30. Interest & other income			
Interest on FDR		413,091	409,915
Dividend income		294,500	99,533
Insurance claim received		1,746,565	489,620
Others Income		2,393,758	4,353,553
Cash Incentive		8,759,700	-
Gain/(loss) on sale of marketable securities (Note 30.a.1)		(1,350)	(4,919,681)
		13,606,264	432,941
30.a Interest & other income			
Interest on FDR		413,091	409,915
Dividend income		294,500	99,533
Insurance claim received		1,746,565	489,620
Others Income		1,579,164	4,353,553
Cash Incentive		8,759,700	-
Gain/(loss) on sale of marketable securities (Note 33.a.1)		(1,350)	(4,919,681)
		12,791,670	432,941

SL No.	Particulars	Amount in BDT	
		July 2022 to September 2022	July 2021 to September 2021
30a.1	Income on sale of marketable securities		
	Gain/(loss) on sale of marketable securities	-	(4,917,731)
	Interest on portfolio credit and others	(1,350)	(1,950)
		<u>(1,350)</u>	<u>(4,919,681)</u>

31. Current tax

Profit before tax	138,820,277	120,549,711
Add: Accounting depreciation	88,686,424	77,620,758
Less: Tax depreciation	(81,086,951)	(86,896,320)
Taxable income	<u>146,419,750</u>	<u>111,274,149</u>

Income tax provision

Particulars	Taxable Income	Taxable Amount	
		30-Sep-22	30-Sep-21
22.5% income tax on taxable profit	134,361,689	30,231,380	23,903,389
Half of 22.5% Income tax on export net profit	7,870,672	885,451	555,450
Cash Incentive	3,892,889	875,900	
20% income tax on dividend received	294,500	58,900	19,907
Total	146,419,750	32,051,631	24,478,746

32 Earnings per share (EPS)

The computation is given below:

Net profit after tax	169,375,631	70,292,505
Ordinary shares outstanding during the year	234,000,000	234,000,000
Earning per share	<u>0.72</u>	<u>0.30</u>

32a Earnings per share

The computation is given below:

Net profit after tax	99,705,268	95,166,361
Ordinary shares outstanding during the year	234,000,000	234,000,000
Earnings per share	<u>0.43</u>	<u>0.41</u>

33. Net Assets Value (NAV) Per Share

Total Assets	55,597,917,226	48,107,039,047
Total Liabilities	33,918,033,894	28,794,514,305
Net Assets	21,679,883,331	19,312,524,743
No of shares	234,000,000	234,000,000
Net Assets Value (NAV) Per Share	<u>92.65</u>	<u>82.53</u>

33a Net Assets Value (NAV) Per Share

Total Assets	34,672,360,384	30,260,976,491
Total Liabilities	19,496,093,661	17,382,397,993
Net Assets	15,176,266,722	12,878,578,498
No of shares	234,000,000	234,000,000
Net Assets Value (NAV) Per Share	<u>64.86</u>	<u>55.04</u>

SL No.	Particulars	Amount in BDT	
		July 2022 to September 2022	July 2021 to September 2021

34. Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018:
Reconciliation of Net operating cash flow under Indirect Method:

Particulars	July 2022 to September 2022	July 2021 to September 2021
Net profit before tax	214,380,954	95,984,096
Workers profit participation fund	6,941,014	6,027,486
Interest & other income	(12,791,670)	(432,941)
Financial expenses	68,321,625	49,013,335
Depreciation	161,681,296	102,588,606
Increase/(Decrease) in inventory	24,914,478	121,864,358
Increase/(Decrease) in receivables	(3,136,990,567)	(113,900,657)
Increase/(Decrease) in advance deposit & prepayments	(193,634,989)	190,523,614
Increase/(Decrease) in employee benefit	2,294,004	
Increase/(Decrease) in payable	3,401,484,500	(105,484,531)
Increase/(Decrease) in accrued expenses	1,026,877	19,284,497
Income taxes paid	(10,321,675)	(8,640,953)
Foreign exchange gain/(loss)	-	-
Net cash flow from operating Activities	<u>527,305,847</u>	<u>356,826,909</u>
34.1 Net operating cash flow per share	<u>2.25</u>	<u>1.52</u>

34.a Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2018:

Reconciliation of Net operating cash flow under Indirect Method:

Particulars	July 2022 to September 2022	July 2021 to September 2021
-------------	-----------------------------	-----------------------------

Net profit before tax	138,820,277	120,549,711
Workers profit participation fund	6,941,014	6,027,486
Interest & other income	(12,791,670)	(432,941)
Financial expenses	20,267,339	19,404,160
Depreciation	88,686,424	77,620,758
Increase/(Decrease) in inventory	13,819,467	13,812,261
Increase/(Decrease) in receivables	2,427,018	(34,423,681)
Increase/(Decrease) in advance, deposit & prepayments	(235,152,948)	224,642,035
Increase/(Decrease) in employee benefit	(1,484,030)	
Increase/(Decrease) in payable	9,981,030	(52,423,059)
Increase/(Decrease) in accrued expenses	1,026,878	3,877,108
Income taxes paid	(10,321,675)	(8,640,953)
Net cash flow from operating activities	<u>22,219,124</u>	<u>370,012,884</u>
34a.1 Net operating cash flow per share	<u>0.09</u>	<u>1.58</u>

 Chairman
 Managing Director
 Director
 Chief Financial Officer

 Company Secretary